CHU de Besançon-Hôpital Saint-Jacques
About CHU de Besançon-Hôpital Saint-Jacques
"Centre hospitalier universitaire (CHU) de Besançon. Etablissement public de santé, qui assure une triple mission : soins, enseignement et recherche."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Gilead Sciences
2
Institut National de la Santé Et de la Recherche Médicale, France
1
MedImmune LLC
1
Pfizer
1
Clinical Trials at CHU de Besançon-Hôpital Saint-Jacques
During the past decade, CHU de Besançon-Hôpital Saint-Jacques conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
2004-11-01
2006-05-01
Completed
6,635
Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women
2009-11-01
2010-07-01
Completed
110
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
2010-11-01
2013-01-01
Completed
1,101
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
2011-11-01
2014-12-01
Completed
438
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
2011-12-01
2014-12-01
Completed
439
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Besançon-Hôpital Saint-Jacques"
#1 collaborator was "MCM Vaccines B.V." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at CHU de Besançon-Hôpital Saint-Jacques
According to Clinical.Site data, the most researched conditions in "CHU de Besançon-Hôpital Saint-Jacques" are
"Acquired Immunodeficiency Syndrome" (2 trials), "HIV Infections" (2 trials), "Influenza" (1 trials), "Psoriasis" (1 trials) and "Respiratory Syncytial Virus Infections" (1 trials). Many other conditions were trialed in "CHU de Besançon-Hôpital Saint-Jacques" in a lesser frequency.
Clinical Trials Intervention Types at CHU de Besançon-Hôpital Saint-Jacques
Most popular intervention types in "CHU de Besançon-Hôpital Saint-Jacques" are "Biological" (3 trials), "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "FTC/TDF" (2 trials), "Stribild" (2 trials), "CP 690,550 10 mg" (1 trials), "CP 690,550 5 mg" (1 trials) and "Etanercept 50 mg" (1 trials). Other intervention names were less common.
Clinical Trials Genders at CHU de Besançon-Hôpital Saint-Jacques
The vast majority of trials in "CHU de Besançon-Hôpital Saint-Jacques" are
4 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at CHU de Besançon-Hôpital Saint-Jacques
Currently, there are NaN active trials in "CHU de Besançon-Hôpital Saint-Jacques".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 5 completed trials in CHU de Besançon-Hôpital Saint-Jacques,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in CHU de Besançon-Hôpital Saint-Jacques, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 4 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".